Introduction {#s1}
============

Epidermal growth factor receptors (EGFR) are a large family of receptor tyrosine kinases which are overexpressed in many types of cancer\[[@B1]\], including breast\[[@B2]\], lung\[[@B3],[@B4]\], esophageal\[[@B5]\], and head and neck\[[@B6]\]. EGFR and its family members are the major contributors of a complex signaling cascade that modulates proliferation, anti-apoptosis, differentiation, adhesion, migration and survival of cancer cells\[[@B7]\]. Due to their multidimensional role in the progression of cancer, EGFR and its family members have emerged as attractive candidates for anticancer therapy. Currently, there are two classes of anti-EGFR agents: the monoclonal antibodies (cetuximab, panitumumab) and small-molecule tyrosine kinase inhibitors (gefitinib, erlotinib). Cetuximab (C) is a chimeric monoclonal antibody (MoAb) that binds to the EGFR and blocks the EGFR signaling cascade, thus inhibiting the growth of the tumor\[[@B8]\]. Panitumumab (P) is an anti-EGFR MoAb which, like C, binds to the EGFR to prevent ligand binding and inhibits the subsequent activation of key downstream signaling molecules involved in tumorigenesis\[[@B9]\]. Erlotinib and gefitinib are oral small molecules designed to selectively inhibit the phosphorylation of EGFR intracellular kinase domain \[[@B10],[@B11]\]. In addition, these four drugs have shown clinical benefits in the treatment of many types of malignancy and have been approved for use in cancer therapy by the United States Food and Drug Administration (FDA)\[[@B10]-[@B13]\].

Fatal adverse events (FAEs) are defined as deaths that are usually secondary to the use of the pharmaceutical agent\[[@B14]\]. Patients with cancer may be at an increased risk because of the progressive nature of malignancy as well as the adverse events (AEs) profiles of chemotherapeutic agents. As a result, determining the incidence and risk of drugs related FAEs is important for closely monitoring and planning appropriate strategies to limit their effects. A previous meta-analysis includes a total of 13,827 patients with various advanced solid tumors from 22 phase III RCTs finds that the overall incidence of EGFR-TKIs (gefitinib and erlotinib) related FAEs is 1.9% (95%CI: 1.2-2.9%), and the use of EGFR-TKIs does not increase the risk of FAEs with an RR of 0.99 (95%CI: 0.70-1.41, *p*=0.97)\[[@B15]\]. However, the risk of FAEs associated with EGFR-MoAbs has not been well determined. Although a recent meta-analysis shows that cetuximab does not significantly increase the risk of FAEs in colorectal cancer (OR, 1.41; 95% CI, 0.99-2.03)\[[@B16]\], this meta-analysis is limited to only nine studies examining cetuximab-related FAEs in colorectal cancer, . In addition, the incidence and risk of FAEs associated with panitumumab, a newly approved anti-EGFR MoAbs, has not been assessed. Here, we conduct this meta-analysis of RCTs to determine the incidence and risk of FAEs associated with the clinical use of EGFR-MoAbs cetuximab and panitumumab.

Materials and Methods {#s2}
=====================

Data source {#s2.1}
-----------

Study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@B17],[@B18]\]. We searched the Pubmed (data from 1966 to May 2013), EMBASE (data from 1980 to May 2013), and Cochrane library databases (up to May 2013) for relevant trials. The search was conducted by using the keywords "cetuximab", "C-255", "Erbitux", "panitumumab", "Vectibix", "randomized", "cancer" and was limited to human studies and prospective randomized controlled clinical trials published in English. Abstracts presented at the annual meetings of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) (from 2001 to 2013) were also searched manually using the same keywords to identify relevant clinical trials; Additionally, we searched the clinical trial registration website (http://www.ClinicalTrials.gov) to obtain information on the registered randomized controlled trials (RCTs); however, only trials published in peer-reviewed publications, in full manuscript form, were included. Each publication was reviewed and in cases of duplicate publication only the most complete, recent, and updated report of the clinical trial was included in the meta-analysis

Study selection {#s2.2}
---------------

The goal of this study was to determine the incidence of EGFR-MoAbs associated FAEs and establish the association between treatment with EGFR-MoAbs and the risk of FAEs. Thus, Phase I trials were omitted due to multiple dose level and limited sample sizes. Clinical trials that met the following criteria were included in the meta-analysis: (1) prospective randomized controlled II and III trials of patients with cancer; (2) participants assigned to treatment with approved EGFR-MoAbs cetuximab and panitumumab (alone or in combination); and (3) available data on FAEs.

Data extraction and clinical endpoints {#s2.3}
--------------------------------------

Data extraction was conducted independently by two investigators (L.X. and W.Z.Y.), and any discrepancy between the reviewers was resolved by consensus. For each study, the following information was extracted: author's name, year of publication, trial phase, number of enrolled subjects, treatment arms, number of patients in treatment and control groups when available, underlying malignancy, median age, median treatment duration, median progression-free survival, adverse outcomes of interest (fatal adverse events), name and dosage of EGFR-MoAbs and the dosing schedules used. The primary end point of the analysis was treatment emergent, non-disease-related, fatal adverse events. Adverse events were defined as per versions two or three of the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) criteria\[[@B19]\]. Both versions are similar in defining fatal adverse events as grade five, though version three requires attribution to specific adverse events while version two did not have such requirements. We excluded events that were reported as related to disease progression, but included all events with unspecified attribution and included events regardless of attribution to treatment provided that they were not related to disease progression.

### Statistical analysis {#s2.3.1}

We extracted the number of patients experiencing a FAEs and the total number of patients being treated with the study drug to calculate incidence. For studies with a control group in the same trial, we also calculated and compared the odds ratio (OR) of FAEs. We used the Peto method to calculate ORs and 95% confidence intervals (CIs) because this method provides the best CI coverage and is more powerful and relatively less biased than the fixed or random-effects analysis when dealing with low event rates\[[@B20]\]. To assess the stability of results, sensitivity analysis was carried out by sequential omission of individual studies. Additionally, to test whether effect sizes were moderated by differences in length of treatment, we have carried out meta-regressions with difference in median length of experimental treatments (expressed in weeks) as predictor and odds ratio as dependent variable. Between-study heterogeneity was estimated using the χ^2^-based Q test and I^2^ statistic\[[@B21]\]. The random-effects model was used in presence of heterogeneity, and the fixed-effects model in its absence. We also conducted the following prespecified subgroup analyses: different EGFR-MoAbs, phase of trials and tumor types. In addition, we calculated ORs for each study using an empirical continuity correction in all studies with zeros to investigate the sensitivity and stability of our results. We added kc=R/R+Ω to each control group cell and kt=Ω/R+Ω to the treatment arm cells. 'R' was calculated as the group ratio imbalance and Ω as the estimated pooled odds ratio (Mantel--Haenszel method) in the studies without zero events in both arms\[[@B20]\]. The presence of publication bias was evaluated by using the Begg and Egger tests \[[@B22],[@B23]\]. All statistical analyses were performed by using Stata version 12.0 software (Stata Corporation, College Station, Texas, USA) and Open Meta-Analyst software version 4.16.12 (Tufts University).

Results {#s3}
=======

Our search yielded 913 publications describing the use of cetuximab and panitumumab, and 21 RCTs were finally included in the meta-analysis. The selection process is summarized in [Figure 1](#pone-0081897-g001){ref-type="fig"}. In total, 14,776 patients were investigated in these trials and they had a variety of cancers: colorectal cancer (eleven trials)\[[@B24]-[@B34]\], non-small-cell lung cancer (five trials)\[[@B35]-[@B39]\], head and neck cancer (two trials)\[[@B40],[@B41]\], esophagus carcinoma (one trial)\[[@B42]\], pancreatic cancer (one trial)\[[@B43]\] and breast cancer (one trial)\[[@B44]\]. Sample size were in the range of 62 to 2686 patients, with fourteen trials including \>400 patients each. According to the inclusion criteria of each trial, patients were required to have an adequate renal, hepatic and hematologic function. The median age of study participants was in the range of 52--66 years (some studies only reported the mean age). [Table 1](#pone-0081897-t001){ref-type="table"} reports the study and patient characteristics for the included trials.

![Flow chart of trial selection process in the meta-analysis.](pone.0081897.g001){#pone-0081897-g001}

10.1371/journal.pone.0081897.t001

###### Baseline characteristics of the 21 trials included in the meta-analysis (*n*=14,776).

  **Histology**              **Authors/ year/phase**         **Patients enrolled**   **Treatment Arm**            **Median age (years)**   **Median treatment duration (weeks)**   **Median PFS/TTP (months)**   **Median OS (months)**   **No. for analysis**   **No. of FAEs**
  -------------------------- ------------------------------- ----------------------- ---------------------------- ------------------------ --------------------------------------- ----------------------------- ------------------------ ---------------------- -----------------
  **CRC**                    Van Cutsem E. et al/2007/III    463                     P+BSC                        62                       NR                                      8weeks                        NR                       229                    0
                                                                                     BSC                          63                       NR                                      7.3 weeks                     NR                       234                    0
                             Sobreo A.F. et al/2008/III      1298                    C+CPT-11                     61                       14                                      4                             10.7                     638                    5
                                                                                     CPT-11                       62                       13.1                                    2.6                           10                       629                    2
                             Bokemeyer C. et al/2009/III     341                     C+FOLFOX-4                   62                       24                                      7.2                           NR                       170                    9
                                                                                     FOLFOX-4                     60                       NR                                      7.2                           NR                       168                    5
                             Hecht J.R. et al/2009/IIIB      1053                    P +L-OHP+Bev                 61                       NR                                      10                            19.4                     407                    5
                                                                                     L-OHP+Bev                    62                       NR                                      11.4                          24.5                     397                    0
                                                                                     P+Bev+CPT-11                 60                       NR                                      10.1                          20.7                     111                    2
                                                                                     Bev+CPT-11                   59                       NR                                      11.7                          20.5                     113                    0
                             Van Cutsem E. et al/2009/III    1217                    C+ FOLFIRI                   61                       25                                      8.9                           19.9                     600                    25
                                                                                     FOLFIRI                      61                       26                                      8                             18.6                     602                    24
                             Tol J et al/2009/III            755                     C+ capecitabine +L-OHP+Bev   62                       24                                      9.4                           19.4                     366                    10
                                                                                     Capecitabine +L-OHP+Bev      62                       28                                      10.8                          20.3                     366                    7
                             Maughan T.S. et al/2011/III     1630                    C +chemotherapy              63                       NR                                      8.6                           17                       815                    9
                                                                                     chemotherapy                 63                       NR                                      8.6                           17.9                     815                    10
                             Alberts S.R. et al/2012/III     2686                    C+ mFOLFOX6                  NR                       NR                                      NR                            NR                       1349                   8
                                                                                     mFOLFOX6                     NR                       NR                                      NR                            NR                       1337                   3
                             Saltz L. et al/2012/III         247                     C +Bev+FOLFOX                63.2                     24                                      8.3                           19.5                     123                    6
                                                                                     Bev+FOLFOX                   61.2                     NR                                      11                            21.3                     124                    4
                             Douillard J.Y. et al/2010/III   1183                    P+FOLFOX4                    NR                       NR                                      9.6                           23.9                     539                    6
                                                                                     FOLFOX4                      NR                       NR                                      8.6                           19.7                     545                    5
                             Peeters M. et al/2010/III       1186                    P+FOLFIRI                    NR                       NR                                      5.9                           14.5                     539                    2
                                                                                     FOLFIRI                      NR                       NR                                      3.9                           12.5                     540                    4
  **NSCLC**                  Butts C.A. et al/2007/II        131                     C+ GEM+platinum              66                       15.1                                    5.09                          11.99                    65                     0
                                                                                     GEM+platinum                 64                       13.0                                    4.21                          9.26                     66                     0
                             Lienbaum R. et al/2009/II/      64                      C+PTX                        NR                       16                                      3.4                           NR                       30                     1
                                                                                     bortezomib+PTX               NR                       8                                       1.9                           NR                       29                     1
                             Pirker R.et al/2009/III         1125                    C+ chemotherapy              59                       18                                      NR                            11.3                     548                    15
                                                                                     chemotherapy                 60                       14                                      NR                            10.1                     562                    10
                             Lynch T.J. et al/2010/III       676                     C +chemotherapy              64                       13                                      4.4                           9.69                     325                    0
                                                                                     chemotherapy                 65                       12                                      4.24                          8.38                     320                    2
                             Govindan R. et al/20110/II      101                     C+ chemoradiotherapy         66                       NR                                      NR                            NR                       53                     3
                                                                                     chemoradiotherapy            65                       NR                                      NR                            NR                       50                     2
  **head and neck cancer**   Bonner J.A.et al/2006/III       424                     C+ radiotherapy              56                       8                                       24.4                          49                       208                    0
                                                                                     radiotherapy                 58                       NR                                      14.9                          29.3                     212                    0
                             vermorken J.B. et al/2008/III   442                     C+ chemotherapy              56                       18                                      5.6                           10.1                     219                    10
                                                                                     chemotherapy                 57                       15                                      3.3                           7.4                      215                    7
  **esophagus carcinoma**    Lorenzen S. et al/2009/II       62                      C+5-FU+DDP                   61                       16                                      5.9                           9.5                      32                     0
                                                                                     5-FU+DDP                     62                       12                                      3.6                           5.5                      30                     1
  **pancreatic cancer**      Philip A.P. et al/2010/III      745                     C +GEM                       64.3                     NR                                      3.4                           6.3                      361                    3
                                                                                     GEM                          63.7                     NR                                      3                             5.9                      355                    0
  **MBC**                    Baselga J. et al/2013/II        181                     C +DDP                       53                       13.6                                    3.7                           12.9                     114                    0
                                                                                     DDP                          52                       13.1                                    1.5                           9.4                      57                     0

Abbreviations: PFS, progression-free survival; OS, overall survival; CRC, colorectal cancer; NSCLC, non-small-cell lung carcinoma; MBC, metastatic breast cancer; FAEs: fatal adverse events; C, cetuximab; P, panitumumab; GEM, gemcitabine; BSC, best support care; L-OHP, oxaliplatin; CPT-11, irinotecan; DDP, cisplatin; Bev, bevacizumab; 5-FU, 5-fluorouracil; NR, not reported.

Incidence of FAEs {#s3.1}
-----------------

For the incidence of FAEs, all MoAbs treatment arms were included, representing a total of 7841 patients. By using a random-effects model (heterogeneity test: *I* ^2^=75%; *p*\<0.001), the incidence of FAEs due to MoAbs was determined to be 1.7% (95%CI: 1.1-2.5%). The highest incidence was observed in a phase II trial of cetuximab in non-small-cell lung cancer \[[@B39]\], with a combined incidence of 5.7% (95%CI: 1.8-16.1%). No FAEs were observed in six trials\[[@B24],[@B35],[@B38],[@B40],[@B42],[@B44]\], When stratified by each MoAbs, the incidence was 2.0% (95%CI: 1.3-3.2%) for cetuximab, 0.9% (95%CI: 0.5-1.7%) for panitumumab ([Figure 2](#pone-0081897-g002){ref-type="fig"}). The incidence of FAEs associated with cetuximab was higher than that of panitumumab (2.0% versus 0.9%, *p*=0.007). However, it should be noted that some studies with unusually broad confidence intervals of cetuximab related FAEs were also included for analysis \[[@B35],[@B36],[@B39],[@B42]\], which might indicate less precise results. After excluding there trials, similar incidence of cetuximab related FAEs were observed (1.9%, 95%CI: 1.1-3.0%).

![Forest plot for meta-analysis of incidence of FAEs in cancer patients assigned EGFR-MoAbs.](pone.0081897.g002){#pone-0081897-g002}

Odds ratio of FAEs {#s3.2}
------------------

To investigate the specific contribution of MoAbs to the development of FAEs and exclude the influence of confounding factors such as underlying malignancy, and other therapeutic interventions, we therefore determined the odds ratio (OR) of MoAbs associated FAEs. The pooled results demonstrated that the use of MoAbs significantly increase the risk of developing FAEs with (Peto OR 1.37, 95%CI: 1.04-1.81, *p*=0.024, [Figure 3](#pone-0081897-g003){ref-type="fig"}) using a fixed-effect model (*I* ^2^=0%, *p*=0.84). As some included trials had a wide variation in confidence intervals, which might decrease the precision of combined results, we thus did sensitivity analysis to examine the stability and reliability of the pooled ORs by sequential omission of individual studies. The results indicated that the significance estimate of pooled ORs was not significantly influenced by omitting any other single study except for the trial conducted by Hecht J.R.\[[@B27]\] ([Figure 4](#pone-0081897-g004){ref-type="fig"}). We then performed a meta-regression analysis to test whether the OR of FAEs varied as function of difference in treatment duration of MoAbs. Since in 8 studies data about treatment duration of MoAbs were not reported, 13 of 21 studies were included in the analysis. Result indicated that there was no significant association between odds ratio and treatment duration of MoAbs (β=0.25; *p*=0.798). Additionally, sub-group analysis found that the use of cetuximab (OR 1.34, 95%CI: 1.00-1.80, *p*=0.052) and panitumumab (OR 1.66, 95%CI: 0.75-3.71; *p*=0.214) was associated with a non-significant increased risk of FAEs. Then, we explored the risk of FAEs among tumor types, and a non-significantly increased risk of FAEs is observed in CRC, NSCLC, head and neck cancer, and pancreatic cancer, while the risk of FAEs did not increase in metastatic breast cancer and esophagus carcinoma. In addition, the highest OR of FAEs was observed in pancreatic cancer patients with OR of 6.94 (95%CI, 0.36-134.87, *p*=0.731). Of note, the confidence intervals were unusually broad indicating low precision. Interestingly, there was a significantly increased risk of FAEs in phase III trials (OR 1.40, 95%CI: 1.05-1.85, *p*=0.021), but the risk did not increase in phase II trials (OR 0.95, 95%CI: 0.23-3.87, *p*=0.939) ([table 2](#pone-0081897-t002){ref-type="table"}).

![Odds ratio of EGFR-MoAbs associated FAEs versus control from randomized controlled trials of patients with cancer.](pone.0081897.g003){#pone-0081897-g003}

![Meta-analysis of FAEs associated with EGFR-MoAbs versus control: 'leave-one-out' sensitivity analysis.](pone.0081897.g004){#pone-0081897-g004}

10.1371/journal.pone.0081897.t002

###### Incidence and relative risk of FAEs with EGFR-MoAbs according to tumor types, EGFR-MoAbs and phases of trials.

  **Groups**             **Studies, n**   **Fatal Adverse Events, No./Total No.**   **Incidence (95%CI), %**   **OR (95% CI**)   **Statistical model**   ***P* value**   
  ---------------------- ---------------- ----------------------------------------- -------------------------- ----------------- ----------------------- --------------- -------
  **Overall**            21               119/7841                                  87/7775                    1.7 ( 1.1-2.5)    1.37 (1.04-1.81)        Fixed           0.024
  **Tumor types**                                                                                                                                                        
  CRC                    11               87/5886                                   64/5879                    1.6 (0.9-2.7)     1.37 (0.99-1.89)        Fixed           0.058
  NSCLC                  5                19/1021                                   15/1027                    2.5 (1.1-5.6)     1.28(0.65-2.53)         Fixed           0.457
  Head and neck cancer   2                10/427                                    7/427                      1.4 (0.1-20.5)    1.42 (0.54-3.73)        Fixed           0.482
  **EGFR-MoAbs**                                                                                                                                                         
  Cetuximab              17               104/6016                                  78/5937                    2.0 (1.3-3.2)     1.34 (1.00-1.80)        Fixed           0.052
  Panitumumab            4                15/1825                                   9/1838                     0.9 (0.5-1.7)     1.66 (0.75-3.71)        Fixed           0.214
  **Phases of trials**                                                                                                                                                   
  Phase II               5                4/294                                     4/232                      2.8 (1.1-6.7)     0.95 (0.23-3.87)        Fixed           0.939
  Phase III              16               115/7547                                  83/7543                    1.6 (1.0-2.5)     1.40 (1.05-1.85)        Fixed           0.021

Abbreviations: NSCLC, non-small-cell lung cancer; CRC, colorectal cancer; OR, odds ratio.

Sensitivity analysis {#s3.3}
--------------------

Sensitivity analyses using an empirical continuity correction \[[@B20]\] (fixed Mantel-Haenszel OR: 1.37, 95%CI: 1.04-1.80), with a continuity of 0.5 correction (fixed Mantel-Haenszel OR: 1.38, 95%CI: 1.04-1.82), or without a continuity correction (fixed Mantel-Haenszel OR: 1.35, 95%CI: 1.03-1.77) showed results similar to those of the primary analysis ([table **3**](#pone-0081897-t003){ref-type="table"}).

10.1371/journal.pone.0081897.t003

###### Sensitivity analyses for the outcome of FAEs.

  **Sensitivity analysis**          **Statistical model**   **OR (95%CI)**
  --------------------------------- ----------------------- ------------------
  Empirical continuity correction   Fixed (MH)              1.37 (1.04-1.80)
  No continuity correction          Fixed (MH)              1.35 (1.03-1.77)
  A continuity correction of 0.5    Fixed (MH)              1.38 (1.04-1.82)

Abbreviation: CI, confidence interval; MH, Mantel-Haenszel test.

Publication bias {#s3.4}
----------------

No evidence of publication bias was detected for the OR of FAEs in this study by either Begg or Egger's test (OR of FAEs: Begg's test *p*=0.343; Egger's test *p*=0.071).

Discussion {#s4}
==========

This meta-analysis provides a comprehensive assessment of the risk of FAEs associated with EGFR-MoAbs. A total of 14,776 patients who received either MoAbs or non-MoAbs regimens are identified from 21 clinical trials. Our pooled results indicate that the overall incidence rate of FAEs is 1.7% (95%CI: 1.1-2.5%). Sub-group analysis demonstrates that the incidence of cetuximab-related FAEs is higher than that of panitumumab (2.0% versus 0.9%). For which we suggest two possible explanations: 1) differences in the distribution of tumor types: in our study, panitumumab is only used in colorectal cancer, while cetuximab has been used in many other tumor types including CRC, NSCLC, or head and neck cancer; 2) relative small patients receive panitumumab therapy, thus the power to detect the incidence of FAEs is low. Additionally, we also demonstrate that there is a small, but significantly increased risk of death with these agents when compared to controls, and sensitivity analysis using different statistical models also confirm our pooled results.

We then perform subgroup analysis to explore the potential risk factors for FAEs. Our study finds that the use of cetuximab and panitumumab is associated with a non-significant increased risk of FAEs. Then, we explore the risk of FAEs among tumor types, and a non-significantly increased risk of FAEs is also observed in CRC, NSCLC, head and neck cancer, and pancreatic cancer, while the risk of FAEs does not increase in metastatic breast cancer and esophagus carcinoma. Interestingly, there is a significantly increased risk of FAEs in phase III trials (OR 1.40, 95%CI: 1.05-1.85, *p*=0.021), but the risk does not increase in phase II trials (OR 0.95, 95%CI: 0.23-3.87, *p*=0.939). There are several possible explanations for these findings: the small number of events recorded; under-reporting of rare adverse events in clinical trials (only 18% of included trials reported FAEs associated with EGFR-MoAbs); the fact that clinical trials are usually not designed specifically to address toxic events; and the small number of trials in other tumor types included. In addition, the meta-regression indicates that there is no significant association between the risk of FAEs and treatment duration of MoAbs (β=0.25; *p*=0.798). Based on our results, we could conclude that the use of EGFR-MoAbs is associated with a significantly increased risk of developing FAEs in cancer patients, and the risk of FAEs is not associated with the treatment duration of MoAbs therapies.

Our meta-analysis has some limitations. First, this is a meta-analysis based on published data, and confounding variables at the patient level, such as co-morbidities, concomitant medications, specific age and previous therapies could not be incorporated into the analysis. Another limitation was that all of the included studies were conducted in patients with adequate organ function at study entry, suggesting that rates of FAEs could be higher in common practice. Also the process by which individual clinicians in trials determined whether a patient's death was the result of a study drug, cancer progression or other unrelated causes carried some subjectivity and was a potential source of bias. Additionally, different treatment strategy, duration, and regimens contributed to increase the clinical heterogeneity of the meta-analysis, which made the interpretation of the meta-analysis more problematic, although we performed sub-group analysis and sensitivity analysis. And it is possible that the concomitant administration of other drugs (such as the combination of cetuximab and bevacizumab) in a few of the trials may have contributed to a higher risk of FAEs.

In conclusion, the use of EGFR-MoAbs therapies is associated with a small, but significant increase in the risk of fatal drug-related events. Despite these findings, both cetuximab and panitumumab benefit the overall population of patients with clear FDA-approved indications. As this class of drugs gains greater clinical use, clinicians should be aware of the risks associated with their use and should monitor closely and appropriately use strategies to improve patient outcomes.
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